-
Mashup Score: 11Instant Oncology: Spine SABR - 2 year(s) ago
The author declares no conflicts of interest.
Source: Clinical OncologyCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 3
‘Leadership is a skill like any other – it is a practise-able, learnable skill – it is something you can work on’ [1]. These are the words of Simon Sinek, one of the best-known leadership gurus and author of the global bestseller Start with why: how great leaders inspire everyone to take action [1]. Leadership can be defined as the ability to influence people towards a changed situation or state.
Source: Clinical OncologyCategories: Latest Headlines, Oncologists2Tweet-
Context: Clinical Oncology invited a debate on Nurture vs Nature in leadership development. Our ‘counter’ article taking the stance that the majority of leadership skills can be learned is found here: https://t.co/09uC4X1hBD @YatTsang @yESTROCommittee @StevenFPetit @achoud72
-
-
Mashup Score: 0The National Lung Cancer Audit: The Impact of COVID-19 - 2 year(s) ago
Since 2014, the National Lung Cancer Audit (NLCA) has been evaluating the performance of the UK NHS lung cancer services against established standards of care. Prior to the onset of the COVID-19 pandemic, the NLCA’s annual reports revealed a steady stream of improvements in early diagnosis, access to surgery, treatment with anti-cancer therapies, input from specialist nursing and survival for…
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
November Editor's Choice #freeaccess Article: The National Lung Cancer Audit: The Impact of COVID-19. Read today https://t.co/6SJiGch1Hb @RCRadiologists @ClinOncology
-
-
Mashup Score: 3Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer – A Done Deal? - 2 year(s) ago
Stereotactic ablative radiotherapy (SABR) is an important curative-intent treatment option for early-stage non-small cell lung cancer. It offers good cancer control without invasive surgery and has become the standard of care for medically inoperable patients. The literature on SABR for early-stage non-small cell lung cancer is substantial and continues to grow. However, there remain areas of…
Source: Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
People from multiple countries around the world continue wondering if Lung SBRT is a done deal. #lcsm #radonc https://t.co/3WZeS92eTV https://t.co/STbRQUFIjw
-
-
Mashup Score: 7
Currently, the Royal College of Radiologists are updating their review of the use of radiotherapy for treating benign conditions. It is hoped that this editorial will help to raise awareness of the wider potential use of radiation, beyond malignancy [1].
Source: Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Monthy_A: Is There Still a Role for Radiation Therapy in the Management of Benign Conditions? #radonc https://t.co/WT9dx6BmE3
-
-
Mashup Score: 0Checklist for Improving Patient Communication on Bladder Preservation Options: The Patient Advocate Perspective - 2 year(s) ago
Trimodal therapy (TMT) – maximal transurethral resection of bladder tumour followed by chemotherapy and radiation – is an effective treatment for some patients diagnosed with muscle-invasive bladder cancer. Yet eligible patients are not always offered this option or are unclear that this option is (or was) appropriate, desirable and available to them. Communication challenges are a critical…
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
October Editor's Choice #freeaccess article: Checklist for Improving Patient Communication on Bladder Preservation Options: The Patient Advocate Perspective Read now https://t.co/fRyToBkgZu @RCRadiologists @ClinOncology
-
-
Mashup Score: 0
To evaluate diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for the prediction of disease-free survival (DFS) in patients with locally advanced rectal cancer.
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
September's Editor's Choice #freeaccess article: Dynamic Contrast-enhanced MRI Evaluation of Whole Tumour Perfusion Heterogeneity Predicts Distant Disease free Survival in Locally Advanced Rectal Cancer Read now https://t.co/ewW2jHii6C @RCRadiologists @ClinOncology
-
-
Mashup Score: 0
Risk factors for systemic anticancer therapies (SACTs) administered close to death derived from existing quality indicators are not directly applicable in the clinic, because they condition on future events, which leads to selection bias. This study aimed to adapt a previously suggested indicator for its use in a clinical context and to evaluate it in a real-world, population-based cohort of…
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
August Editor's choice #freeaccess article: Thirty-Day Mortality Following Systemic Anticancer Therapy: Evaluating Risk Factors Without Selection Bias in a Real-World, Population-Based Cohort From 2009 to 2019. Online here https://t.co/iFFq6awHbR
-
-
Mashup Score: 2
The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR…
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
May's Editor's Choice #freeaccess article from Clinical Oncology - UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Read it online now https://t.co/aBHmrIT4O9
-
-
Mashup Score: 1OncoFlash – Research Updates in a Flash! (May edition) - 3 year(s) ago
Randomised single centre double-blind placebo-controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline in patients suffering long-term gastrointestinal adverse effects of radiotherapy for pelvic cancer: The PPALM study. Andreyev, H.J.N. et al. Radiother and Oncol, 2022 [1].
Source: Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our Editors, Cressida Lorimer & Cathryn Crockett, have done all the hard work so you don’t have to. Our new OncoFlash section provides a monthly roundup of the latest research from around the globe. Read the latest OncoFlash article from Clinical Oncology https://t.co/dyv0x4fZZd https://t.co/vWIWF2WCkE
-
RT @radioncoluis: Instant Oncology: Spine SABR https://t.co/bH0j5ZM2hp @SahgalArjun https://t.co/74VVslFtvc